Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.63 |
| ▸ | CLK2 | P49760 | 1/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | BMX | P51813 | 1/20 | 0.59 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323347 | 0.93 | BTK (0.74) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL1322751 | 0.92 | BTK (0.73) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL1321948 | 0.87 | BTK (0.72) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL1323318 | 0.87 | BTK (0.72) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL1322805 | 0.87 | BTK (0.61) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL1322002 | 0.86 | BTK (0.71) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL1322889 | 0.86 | BTK (0.71) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL1322630 | 0.86 | BTK (0.60) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL1322870 | 0.86 | BTK (0.70) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL1322847 | 0.86 | BTK (0.70) | BTKCLK2EGFRBMXJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081923-B1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2016-03-16 | — | — | EP | disclosed |
| EP-2081923-B1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2016-03-16 | — | — | EP | disclosed |
| US-8058446-B2 | [5-(Pyridin-2-ylamino)-6-oxo-1,6-dihydro-pyridin-3-yl]-(3-amido)-benzene derivatives; anticarcinogenic, antiproliferative, antiallergen, and antiinflammatory agents; lymphoma, leukemia, autoimmune diseases; Bruton's tyrosine kinase inhibitors | GILEAD CONNECTICUT, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058446-B2 | [5-(Pyridin-2-ylamino)-6-oxo-1,6-dihydro-pyridin-3-yl]-(3-amido)-benzene derivatives; anticarcinogenic, antiproliferative, antiallergen, and antiinflammatory agents; lymphoma, leukemia, autoimmune diseases; Bruton's tyrosine kinase inhibitors | GILEAD CONNECTICUT, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058446-B2 | [5-(Pyridin-2-ylamino)-6-oxo-1,6-dihydro-pyridin-3-yl]-(3-amido)-benzene derivatives; anticarcinogenic, antiproliferative, antiallergen, and antiinflammatory agents; lymphoma, leukemia, autoimmune diseases; Bruton's tyrosine kinase inhibitors | GILEAD CONNECTICUT, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2081923-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008033854-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033854-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | BTK 1/4885CLK2 2498/4885EGFR 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.